“ATCC in recent years launched a new initiative to provide custom biological-based Contract Research Organization (CRO) services and standards for the life sciences community, with a focus on biotech and pharma,” Scott Siegel, VP of Corporate Development and Chief Business Officer at ATCC, told Outsourcing-Pharma.com.
As part of this initiative, Siegel said the partnership with BioAgilytix represents “an important step forward.”
The agreement will span multi-year and involves a co-marketing arrangement across ATCC’s complementary areas of cell biology services.
Specifically, ATCC will offer tool and reagent development and storage services, including custom-engineered cell lines and primary cells to complement BioAgilytix’s assay solutions.
“As a 90-year old life sciences institution, it is critical for ATCC to continuously seek ways to evolve and continue our mission of enabling important R&D activities that drive scientific discoveries and advancements,” Siegel explained.
“One of our strategic goals is to develop additional scientifically-relevant products and services, and key to that goal is the expansion of our custom biological-based Contract Research Organization (CRO) services and standards,” he added.
With this goal in mind, the company evaluated external opportunities in the bioanalytical space and chose BioAgilytix as a partner.
Through the strategic partnership, Seigel explained the companies’ complementary capabilities provide the market with “a total assay solution” to facilitate “the rapid and efficient development of important new medicines.”
Additionally, a minority equity investment on the part of ATCC signals the company’s commitment to the relationship and provides the company with a seat on BioAgilytix’s commercial advisory board.
Now that the agreement is signed, Siegel said ATCC is planning a kick-off meeting with BioAgilityix to begin implementing co-marketing plans.